Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71%
Portfolio Pulse from Vandana Singh
Regeneron Pharmaceuticals announced updated data from two Phase 2 expansion dose cohorts of linvoseltamab in patients with relapsed/refractory multiple myeloma, showing a 71% response rate. The LINKER-MM1 trial will form the basis of planned submissions to regulatory authorities, including the FDA, later this year. Regeneron also announced data from three independent cohorts of fianlimab and Libtayo in adults with advanced melanoma, demonstrating clinically meaningful and durable results.
May 26, 2023 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals announced positive data from multiple myeloma and advanced melanoma studies, which may lead to regulatory submissions and potential new treatments.
The positive data from the multiple myeloma study and the advanced melanoma study indicate strong potential for Regeneron's products. The planned submissions to regulatory authorities, including the FDA, later this year could lead to new treatments and increased revenues for the company. This news is likely to have a positive impact on Regeneron's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100